Skip to main content

Affymetrix Stock Slides on News of Defective Mouse Arrays: Analysts Not Worried

NEW YORK, March 7 – After Affymetrix disclosed that its U74 Mouse arrays contained defective sequences, the microarray maker’s shares slid nearly 11 percent Wednesday by midday.

The company’s shares were down $5 15/16, at 50 1/16 in early-afternoon trading on the Nasdaq.

Affymetrix stated in an 8-K filing with the Securities and Exchange Commission Wednesday that it had discovered its mouse genome arrays, which it sells as a set of three chips, contained errors in the sequence, which the company obtained from the UniGene database. 

The company said it would replace these defective arrays with newly designed ones, and estimated its replacement costs at $4 million. Additionally, the company said it would have to take out additional product warranty accruals.

But Ellen Lubman, an analyst who covers Affymetrix at Robertson Stephens, said the financial impact of this problem would be limited. 

“The maximum possible charge, if all customers want all new chips (all three of the set) is a $4 million charge broken over the fourth quarter of 2000 and the first quarter of 2001,” Lubman told GenomeWeb.  

In Lubman’s analysis, “Impact to earnings per share was just three cents but [there was] no general impact, because we exclude amortization and such charges.”

Although Affymetrix has not issued a forecast for this year’s revenues, the company’s 2000 revenues totaled $200.8 million and its net loss totalled $33.6 million or $0.61 per share. 

Affymetrix said in the 8-K filing that its recent acquisition of computational genomics company Neomorphic would strengthen its abilities in the future to ensure the accuracy of public domain sequence information. Neomorphic has genome annotation and analysis tools.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.